NRIX Nurix Therapeutics, Inc.

NASDAQ
$23.67

Nurix Therapeutics, Inc. (NRIX) is expected to report earnings on January 11, 2027, after the market close. The consensus earnings estimate is a loss of $0.51 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +6.8% since its last earnings release on October 12, 2026.

Nurix Therapeutics, Inc. Beat Consensus Estimates
Monday, October 12, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Nov 2026
Jan 11
Monday · 4:00 PM ET
Earnings Whisper
-
vs ($0.51)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $22.82

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Nurix Therapeutics, Inc.

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule and cell therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer and other challenging diseases.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.